About us

Pioneering Biological Artificial SuperIntelligence

Owkin is a next-gen AI company building the one AI Scientist, purpose-built for biomedical breakthroughs.
Get in touch
Owkin OrbOwkin team at workOwkin team at work
Play
Video
Introducing Owkin
[
01:08
]
Owkin CEO Thomas Clozel explains Owkin’s agentic infrastructure for biology and the path towards biological artificial superintelligence

What we believe

Automating early R&D with one autonomous AI Scientist

Founded in 2016 by a clinical oncologist and a machine learning pioneer, Owkin was built on a single conviction: AI applied to multimodal patient data should do science, not just support it.

Today, K Pro brings together biological large language models, multimodal patient data, and a decade of biomedical AI expertise into one AI Scientist to enable smarter, faster drug discovery decisions.

Our ambition goes further. We are working towards biological artificial superintelligence: an autonomous, self-improving AI Scientist that exceeds human performance across all life science domains and is capable of running large parts of drug discovery on its own.

Why work with Owkin

02
Owkin is founder-led
Thomas Clozel, MD, Oncologist, and Gilles Wainrib, PhD, Professor of Machine Learning
07
Global reach
Locations in Boston, New York, London, Paris, Nantes, Geneva and Berlin
03
Trusted by top 8 biopharmas
Strategic deals with:
Sanofi - AI drug discovery
BMS - AI drug development 
MSD - AI diagnostics 
200
+
Top team 
Leading experts in data access & data science, medical doctors, biostatisticians, and computational biologists 
10
Scientifically robust
Scientific Advisory Board of the best specialists in their disease area, chaired by Miriam Merad (M.D., Ph.D. Mount Sinai School of Medicine, NYC)
03
First-in-class AI diagnostics
Now developed through Owkin spin out Waiv
Button
CE marked RlapsRisk® BC for breast cancer prognostic risk profiling
CE marked MSIntuit® CRC for colorectal cancer MSI screening
BRCAura RUO to predict germline BRCA1/2 mutations from HR+/HER2- breast cancer images
#
Cutting-edge science & AI
Publications in top scientific journals like Nature Medicine, Nature Communications, and Hepatology
#
Cutting-edge science & AI
Publications in top scientific journals like Nature Medicine, Nature Communications, and Hepatology
104
Academic partners
Across Canada, USA, France, Germany, Spain
156
KOLs
Close relationships with PIs including 141 KOLs with a mean H-index of 49
304
Well-funded
Million dollars raised from leading biopharma companies (Sanofi & BMS) and venture funds (F-Prime, Google Ventures & Bpifrance Large Ventures, among others)

Leadership team

We work together to outsmart disease

Meet our leadership team, board, and investors
Button

Learn more about what we do

Our Vision

Owkin's AI Scientist

We're building thousands of AI scientists that work 24/7 to accelerate medical breakthroughs, to compress decades of discovery into years.

Find out more
K Pro
Get answers in minutes, not hours, with K Pro

The AI agent for biology, powered by multimodal patient data, for smarter biopharma decision making.

Discover K Pro
Button